These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12088118)

  • 1. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
    Buzdar A; Hayes D; El-Khoudary A; Yan S; Lønning P; Lichinitser M; Gopal R; Falkson G; Pritchard K; Lipton A; Wolter K; Lee A; Fly K; Chew R; Alderdice M; Burke K; Eisenber P;
    Breast Cancer Res Treat; 2002 May; 73(2):161-75. PubMed ID: 12088118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination].
    Chevallier B; Spielmann M; Marty M; Serin D; Pouillart P; Tubiana Hulin M; Mignot L; Pujade Lauraine E; Krams M; Mertens H
    Bull Cancer; 1993 Jul; 80(7):624-8. PubMed ID: 8204943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Droloxifene, a new antiestrogen: its role in metastatic breast cancer.
    Rauschning W; Pritchard KI
    Breast Cancer Res Treat; 1994; 31(1):83-94. PubMed ID: 7981460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droloxifene, a new antiestrogen, in advanced breast cancer. A double-blind dose-finding study. The Droloxifene 002 International Study Group.
    Deschênes L
    Am J Clin Oncol; 1991; 14 Suppl 2():S52-5. PubMed ID: 1962599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical data for Droloxifene.
    Hasmann M; Rattel B; Löser R
    Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment.
    Haarstad H; Lønning PE; Gundersen S; Wist E; Raabe N; Kvinnsland S
    Acta Oncol; 1998; 37(4):365-8. PubMed ID: 9743458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
    Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
    Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
    Pyrhönen S; Valavaara R; Modig H; Pawlicki M; Pienkowski T; Gundersen S; Bauer J; Westman G; Lundgren S; Blanco G; Mella O; Nilsson I; Hietanen T; Hindy I; Vuorinen J; Hajba A
    Br J Cancer; 1997; 76(2):270-7. PubMed ID: 9231932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.
    Haarstad H; Gundersen S; Wist E; Raabe N; Mella O; Kvinnsland S
    Acta Oncol; 1992; 31(4):425-8. PubMed ID: 1632978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Preliminary dose-finding study.
    Abe O
    Am J Clin Oncol; 1991; 14 Suppl 2():S40-5. PubMed ID: 1962596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer.
    Crump M; Sawka CA; DeBoer G; Buchanan RB; Ingle JN; Forbes J; Meakin JW; Shelley W; Pritchard KI
    Breast Cancer Res Treat; 1997 Jul; 44(3):201-10. PubMed ID: 9266099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial.
    Bruning PF
    Eur J Cancer; 1992; 28A(8-9):1404-7. PubMed ID: 1515258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group.
    Gershanovich M; Garin A; Baltina D; Kurvet A; Kangas L; Ellmén J
    Breast Cancer Res Treat; 1997 Sep; 45(3):251-62. PubMed ID: 9386869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials.
    Kuss JT; Muss HB; Hoen H; Case LD
    Breast Cancer Res Treat; 1997 Feb; 42(3):265-74. PubMed ID: 9065610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.